Low T Marketing Raises Safety Concerns
Testosterone supplements have been touted as somewhat of a cure-all for men suffering from a number of conditions that could be no more than the natural result of aging. With recent reports suggesting that treatments for “low T” could leave users at risk for serious heart conditions, Levy Baldante has decided to offer its take on the matter.
Philadelphia, PA (PRWEB) February 26, 2014
Certain activities that may have been taken for granted in a man’s youth can prove slightly more difficult with time. Energy will flag, athletic ability may suffer, and exhaustion becomes common.
For years, these kinds of things weren’t thought of as maladies, but rather just a standard part of aging. But now, a successful marketing effort has served to label them as side effects of an underlying condition known as andropause, which now carries the far more marketable title of “Low T.”
The Low T fad has grown to become a billion dollar industry, but safety concerns have recently been raised in conjunction with supplements that are designed to restore youthful testosterone levels.
The personal injury firm of Levy, Baldante, Finney, Rubenstein, Cohen & Chizmar, P.C. has paid attention to recent developments and decided the time is ripe to speak on this matter. In his position as a drug and medical device lawyer, Martin G. Rubenstein has a unique perspective on the situation. He hopes that persons who have been provided testosterone supplements and suffered adversity in the form of strokes or heart attacks understand their options:
“The way that marketing has positioned Low T, it’s virtually impossible for an aging male not to qualify for treatment,” said Mr. Rubenstein. “Because of this, otherwise able-bodied individuals whose health issues amount to nothing more than a few more birthdays under their belts have been misled into taking a drug that recent research suggests could have a dangerous effect on heart health. Caution needs to be taken by anyone pondering whether or not a Low T treatment would be right for them.”
The aforementioned research that Mr. Rubenstein is referring to actually involves two recently published studies. Both of those studies highlighted the potential for certain persons undergoing testosterone therapy to be at increased risk for heart attacks, with one study also exploring the heightened exposure to strokes and even death.
The Food and Drug Administration related that research in a Safety Announcement from January 31 that voiced the agency’s intention to revisit whether or not testosterone therapies are safe. This exploration of cardiovascular health issues could prompt subsequent action by the FDA in the future.
“We will continue to monitor the FDA’s findings with regard to testosterone supplements,” said Mr. Rubenstein. “I’ve dealt with a lot of lawsuits surrounding unsafe drugs in the past, and I hope that anyone who has been injured or tragically lost a loved one is willing to mull their options as this situation continues to play out.”
The law firm of Levy, Baldante, Finney, Rubenstein, Cohen & Chizmar, P.C. has been fighting for the rights of injured parties since its founding in the 1960s. Recognized by such organizations as Super Lawyers, the American Association for Justice, and the Trial Lawyers Associations of both Pennsylvania and New Jersey, Levy Baldante is dedicated to assisting persons injured by medical malpractice, automobile accidents, defective products, premises liability, and other instances of personal injury. By visiting Levy Baldante's Low T lawsuit page, interested parties can learn more about the firm’s services.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/02/prweb11613256.htm